BRIVARACETAM

Information current as at: 1 June 2026

PBAC meeting date: July 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Briviact®
Form and strength:
  • Oral solution 10 mg per mL, 300 mL
Submission sponsor:
UCB AUSTRALIA PROPRIETARY LIMITED
Condition/indication:
(therapeutic use)
  • Intractable focal onset seizures
Listing requested:
To request that brivaracetam oral liquid be considered as an exempt item under section 84AH of the National Health Act 1953. Where a pharmaceutical item is determined to be an exempt item, that pharmaceutical item is excluded from fifteen year Anniversary Price, first new brand and price disclosure reductions. Exempt items are not exempt from five and ten year Anniversary Price reductions.
Funding program:
PBS General Schedule
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
Change to existing listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2026 PBAC meeting
Opportunity for consumer comment:
Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
1217
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19